The Medicines Company and Alnylam’s inclisiran needs key differentiators to emphasise its edge in hypercholesteremia

cholesterol
Even if inclisiran has a clear dosing advantage, the way it fits into the treatment paradigm could either lead to clinician pushback or poor patient compliance.